Physician profile
Lorilee S Sutter
NPI 1114906435
$3,644.99
in general payments reported to CMS, 2019-2025
15 companies · $850 in 2025
The $850 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $258 · 2021: $512 · 2022: $309 · 2023: $383 · 2024: $1,185 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330 · Education: $87.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,329.85 |
| Education | $87.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,211.31 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $608.81 | 2019-2025 | Evenity, Prolia, Tavneos |
| Ucb, INC. | $457.03 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $405.27 | 2019-2024 | Benlysta |
| Pfizer INC. | $262.18 | 2020-2024 | |
| Radius Health, INC. | $171.75 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.41 | 2020 | |
| Lilly USA, LLC | $144.92 | 2021-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $87.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $31.82 | 2021 | |
| Fresenius Kabi USA, LLC | $29.26 | 2024 | Idacio |
| Genzyme Corporation | $24.63 | 2019 | |
| Janssen Biotech, INC. | $24.39 | 2024 | Tremfya |
| Actelion Pharmaceuticals US, INC. | $23.73 | 2021 | |
| Mayne Pharma Commercial LLC | $7.01 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorilee Sutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.